Mutation Linked to Increased Risk of Prostate Cancer Mortality
The risk of dying of prostate cancer doubled in the presence of a genetic mutation affecting testosterone production, a large prospective cohort study showed. The 5-year risk of prostate cancer-specific mortality (PCSM) increased from 1.7% to as much as 4%, depending on the genotype of the HSD3B1(1245C) allele. In a subgroup of patients with metastatic […]
Clinical Challenges: Treating AML With IDH1 and IDH2 Mutations
About 20% of acute myeloid leukemia (AML) harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. Within the last decade, treatment for these patients “has changed significantly” with the development of first-in-class IDH1 and IDH2 inhibitors, said Tapan Kadia, MD, of the MD Anderson Cancer Center in Houston. Moreover, “treatment paradigms are […]